Centessa Pharmaceuticals

Centessa has entered a definitive agreement to be acquired by @EliLillyandCo. To our team, investigators, patients, and advocates: thank you! Please refer to today’s full announcement for key information and cautionary statements: investors.centessa.com/news-releases/…

As #SleepAwarenessWeek wraps up, we’re proud of how our team supported the sleep community. Beyond awareness, we’re advancing science with the goal of making a real difference for patients living with sleep-wake disorders.

On #WorldSleepDay, Centessa is proud to welcome Dr. Logan Schneider for a conversation with our team. His work at the intersection of sleep, cognition, and neurodegeneration aligns with our mission to advance transformative therapies in neurological disorders.

This #SleepAwarenessWeek, we are standing alongside the sleep community in spotlighting the profound impact of hypersomnolence disorders on patients and their families.

As we conclude our month-long celebration of women in science, Kristen Sagliani, Associate Director, Clinical Pharmacology, shares how her work helps translate innovative science into clinical progress.

As part of our month-long celebration of women in science, Deepali Gupta, Senior Director, Statistical Programming, Biostatistics, reflects on the impact of her work at Centessa.

Continuing our celebration of International Day of Women & Girls in Science, Eileen Leary, PhD, RPSGT, Senior Director, Clinical Development, shares what inspired her career in science.

In honor of International Day of Women & Girls in Science, Centessa is celebrating our female colleagues all month! Today, we spotlight Beatka Zakrzewski, VP, Finance, who shares what science—and her work at Centessa—means to her.

Today is International Day of Women & Girls in Science. We’re proud to celebrate the women of Centessa—and across our industry—whose expertise and leadership drive innovation forward.

This February and March, Centessa’s leadership team will participate in upcoming @Guggenheim, TD Securities, @LeerinkPartners, and @Jefferies conferences. Learn more in our latest press release:investors.centessa.com/news-releases/…

Centessa is presenting new preclinical data supporting the potential expansion of OX2R agonists into neuropsychiatric indications at the 64th ACNP Annual Meeting. Check out our poster on our website after the presentation concludes and learn more here: investors.centessa.com/events-present…

CNTA is pleased to announce that Mario Alberto Accardi PhD, has been appointed CEO and a member of the Board. See release here: investors.centessa.com/news-releases/…

In November and December, members of Centessa’s management team will participate in @GuggenheimPtnrs, @Jefferies, @PiperSandler, @EvercoreInc, and @Oppenheimer conferences. Details in our latest press release: investors.centessa.com/news-releases/…

This morning, CNTA reported Q3FY25 financial results and provided updates on its potential best-in-class orexin receptor 2 (OX2R) agonist program. Highlights from today’s release are below, and you can find the full release on our website at investors.centessa.com/news-releases/…